Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026

Eyestem Research presented clinical data for Eyecyte-RPE, an investigational retinal pigment epithelium (RPE) cell therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), at EURETINA 2026 in Vienna. A mean best-corrected visual acuity (BCVA) gain of about 11 letters, maintained at 18 months, comes from a nine-participant Phase 1 dose-escalation cohort. The randomized Phase 2 study is ongoing, and its longest-treated patients had reached about six months of follow-up.

Clinical Program

• Developer: Eyestem Research.
• Indication: GA secondary to dry AMD.
• Product: Eyecyte-RPE, RPE cells delivered into the subretinal space to support damaged retinal tissue.
• Phase 1: Dose escalation, nine participants across three doses; mean BCVA gain of about 11 letters maintained at 18 months.
• Phase 2: Randomization to treatment or observation; interim data presented at EURETINA with limited follow-up.
• Safety: Procedure-related complications reported in the interim program, including endophthalmitis.

Combining the Phase 1 and Phase 2 time points into a single durability claim would overstate what the controlled study has shown to date.

How RPE Cell Therapy Differs

Most GA therapies under investigation aim to reduce the rate of lesion enlargement with an intravitreal agent. RPE cells support photoreceptor maintenance, metabolism and normal retinal function, and their loss drives the progressive deterioration seen in GA. Subretinal transplantation seeks to address that tissue damage directly. It requires surgery and an assessment of whether transplanted cells survive, integrate and support the photoreceptors that remain viable.

Interpreting the Visual Acuity Gain

Visual acuity alone is an incomplete measure of restored function. Fixation changes, learning effects and concurrent cataract or retinal changes can influence the result. Masked imaging, microperimetry and comparison with untreated eyes will help determine whether the gain reflects restored macular function. The available findings involve small patient groups, so the size of any treatment effect remains uncertain. Randomized controlled evidence will establish the magnitude and consistency of any benefit.

Patient Selection and Surgical Risk

A meaningful gain could justify a greater procedural burden for carefully selected patients, particularly where disease has destroyed native RPE but left rescuable photoreceptors. Identifying those patients is the central unanswered question: an eye with extensive photoreceptor loss may have little substrate for improvement even if transplanted cells engraft.

The reported complications, including endophthalmitis, show that efficacy must be weighed against real operating-room risk. The next milestones are larger patient populations, longer follow-up, the randomized Phase 2 comparison, continued evaluation of surgical delivery and safety, and data on cell survival.

Conclusion

The sustained 11-letter signal arose in a nine-person Phase 1 cohort, and the randomized Phase 2 comparison is still immature. A restorative claim for Eyecyte-RPE requires evidence of reproducible functional benefit with acceptable surgical risk.

The post Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026 appeared first on Ophthalmology Breaking News.

Source: ophthalmologybreakingnews.com
Author: OBN Editorial Team | Date: 2026-10-05 09:00:00